Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 133

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1A
Chunk 133
---
 additional new products or to expand into foreign markets. Accordingly, our ability to commercialize Spryng®
and other products may be dependent on our receipt of the net proceeds from our future financings. We also had an investor subscribe
to a $5 million Series B Preferred stock offering whereby $600,000 has been received by March 31, 2025. The remaining $4.4 million is
expected to be received just prior to the filing of this Form 10-K.

Along
with establishing effective production, marketing, sales, and distribution of Spryng® and other products, we believe that
our future capital requirements depend upon the timing and costs of many factors with some of them beyond our control, including our
ability to establish an adequate base of veterinarian clinics using our products, costs in obtaining patents and any required regulatory
approvals for future products, costs of any future target animal studies, costs related to new product development, costs of finished
product inventory, expenses to attract and retain skilled personnel as needed, increased costs related to being a listed public company,
and the costs of any future acquisitions of existing companies or IP technologies. There is no assurance that future additional capital
will be available to us as needed, or if available upon terms acceptable to us.

Risks
Relating to Our Business and Industry

We
have a limited operating history upon which to base an evaluation of our business prospects.

We
were incorporated in March 2009 and have a limited operating history upon which to base an evaluation of our business prospects. We did
not begin generating notable revenues from the sale of Spryng® until the second quarter of fiscal 2023. Our limited operating
history makes an evaluation of our business and prospects very difficult. Our prospects must be considered speculative, especially considering
the risks, expenses, and difficulties frequently encountered in the establishment of an early-stage company. Our ability to operate our
business successfully remains unknown and untested. If we cannot commercialize our products effectively, or are significantly delayed
or limited in doing so, our business and operations will be harmed substantially, and we may even need to cease operations.

We
are substantially dependent upon the success of Spryng® and any failure of Spryng® to achieve market acceptance would harm us
significantly.

We
have one lead product, Spryng®, which is in commercial production. Our future prospects rely heavily on the successful
marketing of this product. In addition to establishing effective production, marketing, sales, distribution